{"nct_id":"NCT06170788","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","status_verified_date":"2025-10","start_date":"2023-12-15","start_date_type":"ACTUAL","primary_completion_date":"2028-01-25","primary_completion_date_type":"ESTIMATED","completion_date":"2030-05-27","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}